[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-mass-and-strength\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-mass-and-strength":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,76,88,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100054212","effects-of-resistance-exercise-among-tgd-individuals-initiating-estrogen-based-gender-affirming-hormone-therapy-100054212",false,"NCT07400419","Effects of Resistance Exercise Among TGD Individuals Initiating Estrogen-Based Gender-Affirming Hormone Therapy","STRENGTH","Inclusion Criteria:\n\n* ≥ 18 years\n* Initiating GAHT with estradiol (oral, sublingual, patch, injection) AND androgen suppression (leuprolide, spironolactone or bicalutamide)\n* Identifies as either a transgender female\u002Fwoman, gender-diverse, non-binary, gender non-confirming, gender-fluid, and\u002For gender-queer\n* Assigned male sex at birth\n\nExclusion Criteria:\n\n* Current condition(s) which may preclude the ability to participate in a resistance exercise program (including but not limited to conditions which may significantly impair mobility and balance)\n* Current condition(s) where resistance exercise program may be contraindicated (including but not limited to decompensated heart failure, unstable ischemic heart disease, pulmonary hypertension, aortic aneurysm, moderate to severe valvopathies, and\u002For moderate to severe chronic respiratory insufficiency)\n* Use of testosterone therapy for \\> 1 month in the last 6 months\n* Use of gender-affirming hormone therapy with androgen\u002Ftestosterone suppression and\u002For estradiol therapy within 1 year of enrollment\n* Use of gender-affirming hormone therapy with androgen\u002Ftestosterone suppression and\u002For estradiol therapy for \\> 1 year at any time period prior to enrollment\n* History of an orchiectomy\n* Current resistance exercise (including but not limited to use of resistance bands, suspension equipment, body weight exercise, free weight exercise) of 60 minutes or greater per week\n* Enrollment in another study that the study investigators deem as potentially interfering with study participants or study endpoints","MALE","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","Estrogen-dominant gender-affirming hormone therapy (GAHT) is standard of care for transgender women and gender-diverse individuals and typically consists of estrogen together with anti-androgen\u002F testosterone therapy. Estrogen and testosterone balance influences fat and muscle mass, muscular strength and the development of sarcopenia. Sarcopenia, a condition characterized by the loss of muscular mass, strength, and function, in turn, is associated with increased mortality and adverse health outcomes. Estrogen-dominant GAHT may have deleterious effects on body composition and muscular performance that place TGD individuals at-risk for sarcopenia. As part of NCT04128488, our investigative team found that appendicular lean mass (ALM)\u002F height2 decreases after estrogen-based GAHT, thereby portending a higher risk for sarcopenia after GAHT. Early recognition of the changes in body composition and muscular performance leading to sarcopenia are critical, providing potential avenues to intervene and abrogate untoward downstream health effects. A promising intervention is resistance exercise, which has been shown in select populations to improve muscular mass and strength and reduce fat mass, and, thus, mitigate progression to sarcopenia in at-risk populations. For this prospective, pilot clinical trial, investigators will enroll participants who are about to be initiated on estrogen-dominant gender-affirming hormone therapy. Investigators will be randomizing participants 1:1 to either an at-home resistance exercise intervention or no exercise intervention (nutritional and exercise counseling only) for 12 weeks and assess muscle mass, strength, and function both before and after this 12-week period. The exercise intervention group will be provided with the necessary materials to complete the exercise program along with weekly virtual visits with our study team in order to learn their assigned exercises for the week. Further, survey tools will be administered to ascertain whether the resistance exercise intervention may affect gender congruence.",[26],"Muscle Mass and Strength",[28,29,30,31],"Transgender women","Gender-Diverse","Estrogen-dominant gender-affirming hormone therapy","Sarcopenia","RECRUITING","2026-07-09",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2026-04-16",{"date":40,"type":20},"2028-04-01",{"name":42,"class":43},"Massachusetts General Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100641816","significance-of-estrogen-status-for-muscle-function-physical-fitness-and-physiological-health-parameters---a-comparison-of-age-matched-groups-of-women-before-and-after-menopause-100641816","NCT07649356","Significance of Estrogen Status for Muscle Function, Physical Fitness, and Physiological Health Parameters - a Comparison of Age-matched Groups of Women Before and After Menopause.","Effects of Estrogen on Muscle Gain During 12-weeks of Exercise in Post-menopausal Women","HER-MUSCLEX","Inclusion Criteria:\n\n* Regular menstrual bleeding (21-35 days cycle).\n* At least 9 menstrual cycles the last year\n* Age \\>47 years old\n* BMI 20-30\n\nExclusion Criteria:\n\n* Only premenopausal women: Follicular stimulating hormone \\> 30 mmol\u002FL\n* Systematic strength training during the last year (\\> 1 strength training session per week)\n* Systematic high intensity cardiovascular training during the last year (\\\u003C2 times per week)\n* Injuries to the legs which may prevent participation in the physical training program\n* Magnetizable metals or electrical devices implanted in the body, such as a pacemaker\n* Use of medication that can influence the effect of immobilization and\u002For training\n* Muscular or joint disorders which may affect the results\n* Metabolic diseases (such as diabetes and cardiovascular diseases)\n* Previous or present liver or cancer disease\n* Current or previous thrombosis\n* Porphyria\n* Epilepsia\n* Systemic autoimmune disease\n* Edema\n* Smoking or use of other nicotine containing products\n* Claustrophobia\n* Addictive behavior, defined as abuse of cannabis, opioids, or other intoxicating substances.\n* Lack of ability to cooperate\n* Blood parameters out of normal range at the health check\n* Blood pressure above 140\u002F90 mmHg",true,"FEMALE","47 Years",{"count":57,"type":20},30,"OBSERVATIONAL","As females age and transition through menopause, the decline in oestrogen level profoundly affects skeletal muscle mass and function. HER-MUSCLE aims to unravel the differences in pre and post menopausal women, in regards to muscle size, strength and function.\n\nFocusing on postmenopausal females, an increasingly at-risk demographic, HER-MUSCLE addresses a critical gap in understanding how oestrogen influences muscle mass and function.\n\nThe project involves:\n\n1. Molecular Analysis: Advanced techniques will study the muscle microenvironment, focusing on muscle stem cells (MuSCs), fibro-adipogenic progenitors (FAPs), and other cells critical for muscle regeneration and maintenance.\n2. Mitochondrial Function assessed in vivo via magnetic resonance spectroscopy: The impact of oestrogen on mitochondrial health will be examined, exploring how it preserves mitochondrial function and ability to recovery and resist fatigue in response to muscle contractions.\n\nOur preliminary data indicate that oestrogen can promote muscle protein synthesis. HER-MUSCLE aims to pave the way for novel therapeutic strategies to manage sarcopenia in postmenopausal women, ultimately leading to better health outcomes and enhanced well-being for this growing population segment.",[26,61],"Menopause",[63,64,61,65,66],"Muslce Mass","Muscle Strength","Estrogen","Mitochondria function","2026-06-09",{"date":69,"type":36},"2026-06-16",{"date":71,"type":36},"2026-02-01",{"date":73,"type":20},"2027-08-01",{"name":75,"class":43},"Mette Hansen",{"id":77,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":24,"conditions":80,"keywords":81,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":87,"locationsCount":44},"100623729",{"count":19,"type":20},[23],[26],[28,29,30,31],"2026-03-30",{"date":84,"type":36},"2026-04-06",{"date":38,"type":20},{"date":40,"type":20},{"name":42,"class":43},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":53,"sex":54,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":44},"100628115","function-and-lean-mass-preservation-with-resistance-exercise-during-a-glp-1ra-treatment-100628115","NCT07457437","Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment","Effect of a Progressive Resistance Exercise Program on Muscle Mass and Physical Function During a Tirzepatide Induced Weight Loss in Overweight and Obese Females: a Randomised Parallel Group Study","FLEX","Inclusion Criteria:\n\n* 25-50 years old\n* BMI ≥27 kg\u002Fm2 with one obesity related co-morbidity or a BMI between ≥30 and 35 kg\u002Fm2\n* Female\n\nExclusion Criteria:\n\n* Previous GLP-1RA use\n* Diabetes (Type 1 and 2)\n* Contraindicative health condition to GLP-1\u002FGIP\n* Fail clinically administered health screening form for tirzepatide prescription\n* Pregnant or wanting to become pregnant in the next 6 months\n* Has or has previously had an eating disorder\n* Inability to perform exercise program and exercise tests\n* Advised not to exercise by their general practitioner or medical professional\n* Current or recent injury within the last 6 months that may affect the ability to carry out resistance exercise\n* Has consistently resistance trained previously (\\>10 sessions per year)\n* Currently taking medication or supplements that have been shown to impact muscle function and muscle mass in the last 6 months\n* Current or recent, ≤6 months, smoker\n* Currently on HRT","25 Years","50 Years",{"count":19,"type":20},[23],"This study aims to investigate the effect that a structured, progressive resistance exercise program may have on maintaining the muscle mass and physical function of overweight\u002F obese females whilst they experience a tirzepatide (GLP-1\u002FGIP receptor agonist) induced weight loss.\n\nOverweight and obese females aged 25-50 will be recruited for the study, they will require a BMI of \\>30 or \\>27 with one obesity related comorbidity (excluding diabetes). They will be screened, prescribed tirzepatide and then randomly assigned to either the intervention (GLP-1\u002FGIP + Exercise) or the control group (GLP-1\u002FGIP). Groups will then be split into pre and peri menopausal groups to provide a further exploratory pathway looking analysing if the menopause transition may have any effect on our outcome variables. This was proposed as in the UK females are more likely to begin GLP-1RA treatment.\n\nBoth groups will be given an industry standard treatment of tirzepatide over 20 weeks starting at a dose of 2.5mg\u002Fweek and following the dose titration process of +2.5mg\u002Fweek every four weeks outlined by its manufacturers. The Exercise Group (GLP-1 +EXC) will be given the same tirzepatide prescription alongside following a progressive resistance exercise program. The exercise program will follow a similar structure to previous work in which participants will complete a propriety 20-wk whole body, low impact resistance exercise training program four times a week. The exercise sessions will be up to an hour and will be instructor lead by video and supervised by a member of the research team at The University of Exeter.",[26,102,103],"Obesity & Overweight","Physical Function",[105,106,107,108,109],"Maintaining muscle mass on GLP-1RA, physical function on GLP-1RA, tirzepatide, Mounjaro,","Body composition changes during GLP-1\u002FGIP RA weight loss","Resistance exercise and Perimenopause","Lean mass and Tirzepatide","Health outcomes and obesity","2026-03-23",{"date":112,"type":36},"2026-03-27",{"date":114,"type":20},"2026-04-01",{"date":116,"type":20},"2027-12-01",{"name":118,"class":43},"University of Exeter",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":127,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":44},"100611239","protein-supplementation-during-dialysis-prosed-100611239","NCT07237997","Protein Supplementation During Dialysis (PROSED)","Re-examining Nutrition in Dialysis Patients: Nutritional Losses and the Role of Supplementation (Part 2).","PROSED","Inclusion Criteria:\n\n* Age ≥ 18 years (no upper age limit)\n* Patients receiving maintenance dialysis for ≥ three months\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Anticipated live donor kidney transplant and\u002For kidney recovery within the period of sample collection.\n* Anticipated change of dialysis modality within the period of sample collection\n* Severe malnutrition based on either:\n\n  * Renal 7-point Subjective Global Assessment (SGA) scores of 1-2\n  * Global Leadership Initiative Malnutrition (GLIM) Stage 2\n* Protein-losing enteropathy.\n* Persistent nephrotic syndrome with \\>3g\u002Fday urinary protein loss.\n* Active wounds or burns contributing to protein losses as judged by the investigator.\n* Current active acute inflammatory illness (likely to have catabolic effect in the opinion of the investigator).\n* Current malignancy based on recent (\\\u003C12 months) diagnosis and\u002For active treatment for malignancy and\u002For planned treatment for malignancy, excluding non-melanoma skin cancers.\n* Pregnancy (current or planned within duration of study) or breast feeding.\n* People with swallowing difficulties precluding safe ingestion (International Dysphagia Diet Standardization Initiative (IDDSI) level 0 thin fluid).\n* People receiving intradialytic parenteral nutrition or intra-peritoneal amino acids, or any other forms of artificial feeding\n* People prescribed levodopa\n* People who are receiving chronic glucocorticoid therapy (\\>10mg day prednisolone or equivalent for \\>7 days within preceding 90 days).\n* People who are consuming a protein dietary intake above 1.5g protein\u002Fkg\u002Fbody weight.\n* People who, in the opinion of the investigator, will be unable to comply with study protocol requirements.\n* People who are vegan or other religious based dietary restrictions which would prevent them taking the supplement.","ALL",{"count":129,"type":20},114,[23],"When a patient has dialysis some nutrients are lost in the process. Nutritional losses include protein, trace elements (i.e. zinc, copper and selenium) and water-soluble vitamins (Vitamins C and B). These nutrients are essential for normal body function, including a good immune system and nutritional status. For example, on average the protein losses during a dialysis session (the process where the blood is cleaned via a machine and special fluid) is equal to 6g of protein\u002Fday (which is the equivalent of the amount of protein in 1 egg). Protein needs for the general population are 0.8g protein per kg of body weight. Because people on dialysis lose protein via the dialysis, it is thought that these people need to eat more protein. Currently, in clinical practice for people receiving dialysis, the guidelines are to aim for 1.1 -1.4g of protein per kg of body weight. However, the research is old and very weak.\n\nDialysis treatments have changed over the past 40 years, and the investigator does not know if the replacement of these nutritional losses is important to how well people do on dialysis and if they have any effect on survival. Previous research is mostly limited to haemodialysis (a type of dialysis that requires a machine which cleans the patients' blood via special filters) and peritoneal dialysis (this is a type of dialysis which happens via the patients' tummy). There is no research on the nutritional supplementation in home HD and nocturnal HD. Our research will investigate if a higher protein provision leads to a reduction is hospital admissions and improved outcomes in patients receiving dialysis.",[133,134,135,136,137,138,139,140,26,141],"Dialysis Patients","Dialysis","Protein Energy Wasting","Protein Intake","High Protein Dietary Intake","Diet","Diet Therapy","Hospitalisation","Muscle Mass","NOT_YET_RECRUITING","2025-11-14",{"date":145,"type":36},"2025-11-20",{"date":147,"type":20},"2026-01-05",{"date":149,"type":20},"2029-10-30",{"name":151,"class":43},"University of Nottingham"]